**Author details**

Daphne Day1,2, Sophia Frentzas1,2, Cameron A. Naidu2,3, Eva Segelov1,2 and Maja Green2 \*

1 Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia

2 Department of Oncology, Monash University, Clayton, Victoria, Australia

3 Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia

\*Address all correspondence to: maja.green@monash.edu

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**71**

*Current Utility and Future Applications of ctDNA in Colorectal Cancer*

of circulating tumour DNA. Nature Reviews. Cancer. 2017;**17**(4):223-238

[10] Leon SA et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Research.

[11] Stroun M et al. Neoplastic

[12] Diaz LAJ, Bardelli A. Liquid

[13] Jahr S et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Research.

characteristics of the DNA found in the plasma of cancer patients. Oncology.

biopsies: Genotyping circulating tumor DNA. Journal of Clinical Oncology.

1977;**37**(3):646-650

1989;**46**(5):318-322

2014;**32**(6):579-586

2001;**61**(4):1659-1665

[14] Khakoo S et al. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Critical Reviews in Oncology/

Hematology. 2018;**122**:72-82

tumor cells and circulating tumor DNA. Cancer Discovery.

2014;**4**(6):650-661

[15] Haber DA, Velculescu VE. Bloodbased analyses of cancer: Circulating

[16] Gorgannezhad L et al. Circulating

tumor DNA and liquid biopsy: Opportunities, challenges, and recent advances in detection technologies. Lab

on a Chip. 2018;**18**(8):1174-1196

America. 2003;**100**(15):

8817-8822

[17] Dressman D et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proceedings of the National Academy of Sciences of the United States of

*DOI: http://dx.doi.org/10.5772/intechopen.82316*

[1] Li ZZ et al. Mutation profiling in Chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget. 2016;**7**(19):28356-28368

[2] Misale S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;**486**(7404):532-536

[3] Gerlinger M et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine.

[4] Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discovery.

[5] Merker JD et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology. 2018;**36**(16):1631-1641

[6] Nadal C et al. Future perspectives

[7] Garlan F et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clinical Cancer Research.

[8] Mendel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. Comptes Rendus des Seances de la Societe de Biologie et de Ses

[9] Wan JCM et al. Liquid biopsies come of age: Towards implementation

of circulating tumor DNA in colorectal cancer. Tumour Biology. 2017;**39**(5):1010428317705749

2017;**23**(18):5416-5425

Filiales. 1948;**142**:241-243

2012;**366**(10):883-892

2016;**6**(5):479-491

**References**

*Current Utility and Future Applications of ctDNA in Colorectal Cancer DOI: http://dx.doi.org/10.5772/intechopen.82316*
